Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice

Clin Exp Metastasis. 1995 Jul;13(4):296-302. doi: 10.1007/BF00133485.

Abstract

Urokinase-type plasminogen activator (uPA) is a protease involved in the process of tissue remodelling and cell migration in vitro. To explore whether uPA is a prerequisite for human ovarian cancer spread in vivo the expression of uPA was suppressed in human ovarian cancer cells by antisense phosphorothioate oligonucleotides (PS-ODN). The suppression of uPA expression was dependent on PS-ODN concentration and only observed in the presence of liposomes. This phenomenon seemed to be due to the fact that PS-ODNs were taken up by the cancer cells only in concert with liposomes as studied by fluorescently-labeled PS-ODNs using flow cytofluorometry and laser scanning microscopy. uPA-deprived cancer cells exhibited a significantly reduced invasive capacity in vitro compared with untreated cancer cells or cells treated with control PS-ODNs (P = 0.003). The intraperitoneal spread of the cancer cells in vivo was significantly diminished when nude mice were treated with uPA antisense PS-ODNs in comparison with control mice (P = 0.009). These results suggest that uPA expression may be required for spread of human ovarian cancer and that its inhibition could provide a therapeutic approach.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Base Sequence
  • Feasibility Studies
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Molecular Sequence Data
  • Neoplasm Invasiveness / prevention & control
  • Neoplasm Transplantation
  • Oligonucleotides, Antisense / pharmacology*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / enzymology*
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / pathology
  • Thionucleotides / pharmacology*
  • Tumor Cells, Cultured
  • Urokinase-Type Plasminogen Activator / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Thionucleotides
  • Urokinase-Type Plasminogen Activator